KRAS and colorectal cancer: Of 335 colorectal cancers harboring atypical KRAS mutations in the combined cohorts, 317 (94.6%) had no concomitant pathogenic BRAF mutation, with BRAF mutations in the remaining 18 all belonging to class 3 (18/335, 5.4%).